Brokerages Set SAGE Therapeutics Inc (SAGE) PT at $200.58

SAGE Therapeutics Inc (NASDAQ:SAGE) has been given an average rating of “Buy” by the fifteen brokerages that are covering the company, MarketBeat reports. Two equities research analysts have rated the stock with a sell recommendation and thirteen have assigned a buy recommendation to the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $200.58.

Several brokerages have commented on SAGE. Oppenheimer began coverage on shares of SAGE Therapeutics in a research report on Wednesday, October 10th. They set a “buy” rating and a $170.00 target price for the company. Royal Bank of Canada upped their target price on shares of SAGE Therapeutics from $259.00 to $261.00 and gave the company an “outperform” rating in a research report on Monday, November 5th. BidaskClub upgraded shares of SAGE Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Monday. LADENBURG THALM/SH SH set a $210.00 target price on shares of SAGE Therapeutics and gave the company a “buy” rating in a research report on Tuesday, December 11th. Finally, Morgan Stanley upped their target price on shares of SAGE Therapeutics from $228.00 to $230.00 and gave the company an “overweight” rating in a research report on Thursday, October 11th.

Shares of SAGE Therapeutics stock traded down $1.12 on Friday, hitting $125.10. 449,127 shares of the company’s stock traded hands, compared to its average volume of 1,318,216. The stock has a market capitalization of $5.62 billion, a price-to-earnings ratio of -17.64 and a beta of 2.62. SAGE Therapeutics has a one year low of $79.88 and a one year high of $195.97.

SAGE Therapeutics (NASDAQ:SAGE) last issued its earnings results on Tuesday, November 6th. The biopharmaceutical company reported ($2.63) EPS for the quarter, missing the consensus estimate of ($2.41) by ($0.22). During the same quarter in the prior year, the company posted ($1.97) EPS. On average, research analysts forecast that SAGE Therapeutics will post -7.75 earnings per share for the current fiscal year.

Several institutional investors and hedge funds have recently added to or reduced their stakes in SAGE. Franklin Resources Inc. increased its position in shares of SAGE Therapeutics by 66.3% in the 3rd quarter. Franklin Resources Inc. now owns 950,773 shares of the biopharmaceutical company’s stock valued at $134,277,000 after buying an additional 379,121 shares in the last quarter. Millennium Management LLC boosted its stake in SAGE Therapeutics by 622.4% in the 2nd quarter. Millennium Management LLC now owns 379,904 shares of the biopharmaceutical company’s stock worth $59,466,000 after purchasing an additional 327,312 shares during the period. Vanguard Group Inc. boosted its stake in SAGE Therapeutics by 6.9% in the 3rd quarter. Vanguard Group Inc. now owns 4,085,812 shares of the biopharmaceutical company’s stock worth $577,121,000 after purchasing an additional 262,990 shares during the period. Vanguard Group Inc boosted its stake in SAGE Therapeutics by 6.9% in the 3rd quarter. Vanguard Group Inc now owns 4,085,812 shares of the biopharmaceutical company’s stock worth $577,121,000 after purchasing an additional 262,990 shares during the period. Finally, Waddell & Reed Financial Inc. acquired a new position in SAGE Therapeutics in the 2nd quarter worth $34,640,000.

About SAGE Therapeutics

Sage Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system disorders. Its lead product candidate comprises brexanolone, a proprietary intravenous formulation of allopregnanolone that has completed III clinical trials for the treatment of post-partum depression (PPD).

Recommended Story: How is the LIBOR rate calculated?

Analyst Recommendations for SAGE Therapeutics (NASDAQ:SAGE)

Receive News & Ratings for SAGE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAGE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply